Carcinosarcoma of the corpus uteri

Carcinosarcoma of the corpus uteri, also known as malignant mixed Müllerian tumor (MMMT) of the uterus or uterine carcinosarcoma, is a rare and highly aggressive malignant neoplasm arising from the body of the uterus. This tumor is characterized by the presence of both malignant epithelial (carcinomatous) and malignant mesenchymal (sarcomatous) components, making it a biphasic neoplasm. It is now generally classified as a metaplastic or dedifferentiated form of endometrial carcinoma rather than a true sarcoma, as molecular evidence suggests the sarcomatous component derives from the carcinomatous component through epithelial-to-mesenchymal transition. The disease primarily affects the female reproductive system, specifically the uterine corpus (body of the uterus), but it has a strong tendency for early extrauterine spread, including involvement of the pelvic and para-aortic lymph nodes, peritoneum, and distant organs such as the lungs and liver. Key symptoms include abnormal or postmenopausal vaginal bleeding, pelvic pain, a rapidly enlarging uterine mass, and sometimes a polypoid mass protruding through the cervix. Many patients present at an advanced stage, contributing to the poor overall prognosis. Carcinosarcoma of the corpus uteri predominantly occurs in postmenopausal women, with a median age at diagnosis typically in the sixth to seventh decade of life. Risk factors include prior pelvic radiation, obesity, exogenous estrogen use, and tamoxifen therapy. Treatment generally involves total hysterectomy with bilateral salpingo-oophorectomy, pelvic and para-aortic lymph node dissection, and surgical staging. Adjuvant therapy, including platinum-based chemotherapy (commonly carboplatin and paclitaxel) and sometimes radiation therapy, is frequently recommended given the high risk of recurrence. Despite multimodal treatment, the prognosis remains poor, with five-year survival rates significantly lower than those for conventional endometrial carcinomas.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Carcinosarcoma of the corpus uteri